ID   BALM-5
AC   CVCL_5205
DR   Cosmic; 999784
DR   Wikidata; Q54753209
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   DOI=10.11418/jtca1981.15.4_211;
RX   PubMed=160894;
RX   PubMed=2939141;
CC   Population: Caucasian.
CC   Doubling time: 36-48 hours (PubMed=160894).
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C8851; Diffuse large B-cell lymphoma
DI   ORDO; Orphanet_544; Diffuse large B-cell lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_5426 ! BALM-3
OI   CVCL_5427 ! BALM-4
SX   Female
AG   63Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 29-06-23; Version: 14
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In book) ISBN 9780122219702; pp.1-733; Academic Press; London; United Kingdom (2001).
//
RX   DOI=10.11418/jtca1981.15.4_211;
RA   Matsuo Y., Okochi A., Ariyasu T., Iimura E., Ohno T.;
RT   "Identification of cell lines with variable numbers of tandem repeat
RT   (VNTR) amplified by polymerase chain reaction.";
RL   Tissue Cult. Res. Commun. 15:211-219(1996).
//
RX   PubMed=160894; DOI=10.1002/ijc.2910240509;
RA   Lok M.-S., Koshiba H., Han T., Abe S., Minowada J., Sandberg A.A.;
RT   "Establishment and characterization of human B-lymphocytic lymphoma
RT   cell lines (BALM-3, -4 and -5); intraclonal variation in the B-cell
RT   differentiation stage.";
RL   Int. J. Cancer 24:572-578(1979).
//
RX   PubMed=2939141; DOI=10.4049/jimmunol.136.11.4311;
RA   Pesando J.M., Graf L.;
RT   "Differential expression of HLA-DR, -DQ, and -DP antigens on malignant
RT   B cells.";
RL   J. Immunol. 136:4311-4318(1986).
//